Yost Capital Management Llc increased Cullen Frost Bankers Inc (CFR) stake by 20.95% reported in 2017Q3 SEC filing. Yost Capital Management Llc acquired 19,790 shares as Cullen Frost Bankers Inc (CFR)’s stock declined 3.20%. The Yost Capital Management Llc holds 114,270 shares with $10.85 million value, up from 94,480 last quarter. Cullen Frost Bankers Inc now has $6.39 billion valuation. The stock increased 0.56% or $0.56 during the last trading session, reaching $101.16. About 307,471 shares traded. Cullen/Frost Bankers, Inc. (NYSE:CFR) has risen 44.85% since January 17, 2017 and is uptrending. It has outperformed by 28.15% the S&P500.
Analysts expect Zoetis Inc. (NYSE:ZTS) to report $0.66 EPS on February, 15.They anticipate $0.19 EPS change or 40.43% from last quarter’s $0.47 EPS. ZTS’s profit would be $321.61 million giving it 28.98 P/E if the $0.66 EPS is correct. After having $0.65 EPS previously, Zoetis Inc.’s analysts see 1.54% EPS growth. The stock increased 1.30% or $0.98 during the last trading session, reaching $76.52. About 926,164 shares traded. Zoetis Inc. (NYSE:ZTS) has risen 29.89% since January 17, 2017 and is uptrending. It has outperformed by 13.19% the S&P500.
Among 21 analysts covering Zoetis Inc (NYSE:ZTS), 16 have Buy rating, 0 Sell and 5 Hold. Therefore 76% are positive. Zoetis Inc had 67 analyst reports since July 24, 2015 according to SRatingsIntel. The rating was maintained by BMO Capital Markets with “Hold” on Monday, August 7. On Thursday, July 20 the stock rating was maintained by Stifel Nicolaus with “Buy”. As per Friday, November 17, the company rating was maintained by Cowen & Co. Citigroup maintained the stock with “Neutral” rating in Thursday, August 4 report. The firm has “Overweight” rating given on Wednesday, November 29 by Morgan Stanley. Jefferies maintained Zoetis Inc. (NYSE:ZTS) rating on Monday, October 16. Jefferies has “Buy” rating and $76.0 target. As per Thursday, November 16, the company rating was maintained by Jefferies. On Wednesday, August 30 the stock rating was maintained by Stifel Nicolaus with “Buy”. The stock of Zoetis Inc. (NYSE:ZTS) has “Buy” rating given on Monday, July 17 by Cowen & Co. On Tuesday, January 2 the stock rating was maintained by Craig Hallum with “Buy”.
Investors sentiment increased to 1.1 in 2017 Q3. Its up 0.06, from 1.04 in 2017Q2. It increased, as 41 investors sold Zoetis Inc. shares while 233 reduced holdings. 62 funds opened positions while 240 raised stakes. 440.74 million shares or 0.80% less from 444.27 million shares in 2017Q2 were reported. Fort Washington Oh reported 8,145 shares. Wealthfront Inc reported 15,024 shares. Allsquare Wealth Ltd Llc owns 310 shares for 0.02% of their portfolio. 65,239 were accumulated by Tradition Management Lc. Transamerica Advisors holds 0.08% of its portfolio in Zoetis Inc. (NYSE:ZTS) for 10,357 shares. Highland Cap Limited Company reported 0.12% of its portfolio in Zoetis Inc. (NYSE:ZTS). Princeton Strategies Grp Incorporated holds 71,538 shares or 1.23% of its portfolio. Madison Hldg holds 496,231 shares or 0.57% of its portfolio. Findlay Park Prtnrs Limited Liability Partnership invested in 1.34 million shares or 0.84% of the stock. Panagora Asset Management invested in 779,180 shares or 0.2% of the stock. Norinchukin Financial Bank The invested 0.08% of its portfolio in Zoetis Inc. (NYSE:ZTS). Robecosam Ag holds 0.07% of its portfolio in Zoetis Inc. (NYSE:ZTS) for 14,667 shares. King Luther, Texas-based fund reported 1.26 million shares. Andra Ap reported 80,800 shares stake. 55,005 were reported by Baldwin Brothers Incorporated Ma.
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals in the United States and internationally. The company has market cap of $37.29 billion. It offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites, such as fleas, ticks, and worms. It has a 40.29 P/E ratio. The firm also provides medicated feed additives that offer medicines to livestock; and other pharmaceutical products, including pain and sedation, oncology, antiemetic, allergy and dermatology, and reproductive products.
Since October 27, 2017, it had 0 buys, and 2 selling transactions for $4.86 million activity. 41,760 shares were sold by Berman Bobby, worth $4.20 million on Friday, October 27. Wolfshohl Candace K had sold 7,000 shares worth $664,930.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.